United States· US:83107-030_4c20479c-d75a-a0c7-e063-6394a90a9e59
Ethyol
A amifostine product containing amifostine, registered in United States by Legacy Pharma USA Inc.. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Amifostine is registered in 3 of 19 countries.
Countries holding a registration under ATC V03AF05 (amifostine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Amifostine · ATC V03AF05
3 / 19 countries
- Finlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- AMIFOSTINE
- Manufacturer
- Legacy Pharma USA Inc.
- Country
- United States (US)
- ATC code
- V03AF05
- ATC class
- Amifostine
- Defined daily dose
- 1.7 g, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1183107030023 VIAL, SINGLE-DOSE in 1 CARTON (83107-030-02) / 10 mL in 1 VIAL, SINGLE-DOSE (83107-030-01)
- ndc1183107-030-02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
156 interactions on record for amifostine.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amifostine · interactions on record
156 records
- 1 severe
- 125 moderate
- 30 info
Most severe, free to view
- EtelcalcetideH05BX04severe
- PapaverineA03AD01moderate
- MannitolA06AD16moderate
- EpoprostenolB01AC09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Amifostine in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/79fba3ef-f9d8-4bfc-bf26-c90a1e09e71b GET /v1/drugs/79fba3ef-f9d8-4bfc-bf26-c90a1e09e71b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "500",
"substance": "AMIFOSTINE",
"productndc": "83107-030",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/10mL",
"application_number": "NDA020221",
"marketing_category": "NDA"
}See everything about amifostine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.